Hepatitis: Schroder T

Fassio E, Schroder T, Anonymous00128. · Hospital Nacional Prof Alejandro Posadas, El Palomar, Provincia de Buenos Aires, Argentina. · Acta Gastroenterol Latinoam. · Pubmed #18533358 No free full text.

This publication has no abstract.

Paladino N, Fainboim H, Theiler G, Schroder T, Muñoz AE, Flores AC, Galdame O, Fainboim L. · División Inmunogenética, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Av. Córdoba 2351, Buenos Aires 1120, Argentina. · J Virol. · Pubmed #16940525 links to  free full text

Abstract: Elevated levels of interleukin 10 (IL-10) were previously described for chronically hepatitis C virus (HCV)-infected patients. We determined by a sequence-specific oligonucleotide probing technique the IL-10 promoter genotypes in 286 Argentinean HCV patients grouped according to disease outcome. The GG genotype (position -1082) is known to be associated with high IL-10 production, GA is considered an intermediate producer, and AA is associated with low IL-10 production. We found an increase in frequency of the GG genotype in female patients who do not eliminate the virus (RNA(+)). In these patients, the GG frequency was 0.19, versus 0.10 in controls (P = 0.03). This association became more significant in those RNA(+) female patients with elevated hepatic transaminases (GG frequency of 0.25; P = 0.0013). Additionally, this genotype frequency was higher in noncirrhotic female patients than in controls (GG frequency for noncirrhotic female patients was 0.31; P = 0.009). In RNA(-) patients, the GA frequency was elevated compared with that in controls (GA frequency of 0.76 in RNA(-) patients versus 0.48 in controls; P = 0.01), that in all HCV patients (GA frequency of 0.43; P = 0.001), and that in RNA(+) patients (GA frequency of 0.40; P = 0.0005). We conclude that a gender effect is observed with women carrying the GG high IL-10 producer genotype. The higher levels of IL-10 present in those individuals are associated with a higher risk of an inefficient clearance of the HCV and the development of a chronic HCV infection together with a lower risk of progression to cirrhosis in female patients.

Schroder T, Bessone F, Cavallaro S. · Unidad 4, Hepatopatías Infecciosas, Hospital Francisco Javier Mũniz, Ciudad Autónoma de Buenos Aires. · Acta Gastroenterol Latinoam. · Pubmed #16862863 No free full text.

This publication has no abstract.

Oubiña JR, Quarleri JF, Sawicki MA, Mathet VL, Ruiz V, Schroder T, Méndez M, Parera V, Muramatsu H, Battle A, González Cappa SM, Fainboim HA. · Department of Microbiology, Faculty of Medicine, University of Buenos Aires, Paraguay 2155, Piso 11, 1121 Buenos Aires, Argentina. · Intervirology. · Pubmed #11509882 No free full text.

Abstract: To investigate hepatitis C virus (HCV) and GBV-C/hepatitis G virus (HGV) genotype prevalence among HCV-infected porphyria cutanea tarda (PCT) patients, 19 HCV-infected patients with associated PCT were studied. A control group of 53 age-matched HCV-infected patients without associated PCT was selected. Eighteen of the 19 serologically positive HCV-PCT patients showed HCV RNA in serum. Genotype 1b was the most prevalent among both HCV-PCT patients (72.2%; 13/18) and age-matched HCV controls (50.9%; 27/53). Such different genotypic prevalence failed to reach statistical significance (chi(2) with Yates' correction, p = 0.19). The single HCV-PCT patient without detectable HCV RNA was also infected with genogroup 3 GBV-C/HGV. This GBV-C/HGV RNA prevalence (5.3%) among HCV-PCT patients is not statistically different from that observed among Argentine blood donors (5.5%; 11/200). To our knowledge, these results show for the first time the molecular epidemiology of both HCV and GBV-C/HGV associated to PCT in America.

de Larrañaga GF, Harris N, Pierangeli SS, Alonso BS, Schroder T, Fainboim H. · Sección Bioquímica, área Hemostasia y Trombosis, Hospital de Infecciosas F. J. Muñiz, Uspallata 2272, 1282 Buenos Aires, Argentina. · Medicina (B Aires). · Pubmed #11436702 No free full text.

Abstract: Antiphospholipid antibodies (aPL) have been associated with different diseases. They are defined as a large family of immunoglobulins (Ig) of either alloantibodies or autoantibodies. The autoimmune antibodies are associated with venous and/or arterial thrombosis, thrombocytopenia and recurrent fetal loss in the so-called antiphospholipid syndrome or in systemic lupus erythematosus. These antibodies are directed against proteins or phospholipid-protein complexes. On the contrary, antiphospholipid antibodies (alloantibodies) which are found in infectious diseases sera (syphilis, HIV, and other viral diseases), disappear with illness remission and are directed to phospholipids alone (particularly cardiolipin) and are not associated with thrombosis or recurrent fetal loss. However, the role and type of aPL found during hepatic diseases is still unclear. To investigate the prevalence of autoimmune aPL (IgG and IgM) during different hepatic diseases, we have studied 128 patients with hepatitis C virus, hepatitis B virus and hepatic autoimmune diseases without treatment as well as 40 healthy control subjects. We have used a specific ELISA kit, that uses a mixture of phospholipid instead of cardiolipin alone, and allows a better detection of aPL of the autoimmune type. Our results show that autoimmune aPL are not significantly increased in viral hepatic diseases (2%) or autoimmune diseases of the liver (3%) when compared to the control group (0%).